The next three years will be a proving period for Astellas. Its new Corporate Strategic Plan […]
Important disclaimer This article is a general primer. It is intended to give cross-functional teams a […]
Japan is genuinely interesting for companies developing cell therapies, gene therapies and regenerative medicine product. But […]
Japan’s ageing population is enormous. That does not automatically make Japan a good market for your […]
Japan changed important parts of its clinical development system in December 2023, when the Ministry of […]
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]
This article: Japan market entry can produce meetings, contacts and polite interest without producing commercial traction. […]
Japan’s pharmaceutical ecosystem is seemingly undergoing a profound structural shift. If you are targeting the Japanese […]
The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]